Search

Your search keyword '"Mamon, Harvey"' showing total 290 results
Start Over Author "Mamon, Harvey" Language english
290 results on '"Mamon, Harvey"'

5. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Author

Safran, Howard P, Winter, Kathryn, Ilson, David H, Wigle, Dennis, DiPetrillo, Thomas, Haddock, Michael G, Hong, Theodore S, Leichman, Lawrence P, Rajdev, Lakshmi, Resnick, Murray, Kachnic, Lisa A, Seaward, Samantha, Mamon, Harvey, Diaz Pardo, Dayssy Alexandra, Anderson, Carryn M, Shen, Xinglei, Sharma, Anand K, Katz, Alan W, Salo, Jonathan, Leonard, Kara L, Moughan, Jennifer, and Crane, Christopher H

Published
2022
Full Text
View/download PDF

6. Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer

Author

Singh, Harshabad, Klempner, Samuel J., Melnitchouk, Nelya, Chander, Deepak P., Negrea, Ovidiu George, Patel, Anuj K., Schlechter, Benjamin L., Rubinson, Douglas A., Huffman, Brandon M., Nambiar, Chetan, Remland, Joshua, Andrews, Elizabeth, Leahy, Megan E., Brais, Lauren K., Enzinger, Peter C., Mamon, Harvey J., Giannakis, Marios, Meyerhardt, Jeffrey A., Ng, Kimmie, Perez, Kimberly J., Aguirre, Andrew J., Clark, Jeffrey W., Cleary, James M., and Wolpin, Brian M.

Published
2023
Full Text
View/download PDF

11. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

Author

Patel, Jai N., Jiang, Chen, Owzar, Kouros, Mulkey, Flora, Luzum, Jasmine A., Mamon, Harvey J., Haller, Daniel G., Dragovich, Tomislav, Alberts, Steven R., Bjarnason, Georg, Willet, Christopher G., Niedzwiecki, Donna, Enzinger, Peter, Ratain, Mark J., Fuchs, Charles, and McLeod, Howard L.

Published
2021
Full Text
View/download PDF

13. Neoadjuvant short-course radiotherapy or chemoradiation plus consolidative chemotherapy followed by radical operation for locally advanced rectal cancer.

Author

Shing Fung Lee, Pui Lam Yip, Barry Wo, Sean-Man Wong, Natalie, Vellayappan, Balamurugan A., Mamon, Harvey J., and Shing Lee, Francis Ann

Subjects
RECTAL cancer, ABDOMINOPERINEAL resection, CHEMORADIOTHERAPY, TUMOR classification, RADIOTHERAPY, CANCER chemotherapy, TREATMENT failure
Abstract

Introduction: Limited evidence compares short-course radiotherapy (SCRT) and long-course chemoradiotherapy (LCCRT), both of which are followed by consolidative chemotherapy before radical rectal surgery. We conducted a retrospective cohort study to assess treatment response, survival outcomes, and toxicity in patients with locally advanced rectal cancer. Materials and methods: Patients (cT3-4 and/or N+) treated with SCRT or LCCRT, consolidative chemotherapy, or total mesorectal excision between 2013 and 2021 were identified. the cause-specific cumulative incidence of disease-related treatment failure, locoregional recurrence, distant metastases, and overall survival were evaluated using flexible parametric competing risk analysis and Kaplan-Meier methods, adjusted for treatment regimens and clinicopathological factors. A pathological complete response (pCR), tumor downstaging, and toxicity have been reported. Results: Among the 144 patients, 115 (80%) underwent curative rectal surgery. The LCCRT and SCRT groups achieved pCR in 10 (18%) and seven (12%) patients, respectively (odds ratio, 1.68; 95% confidence interval [CI], 0.59-4.78). The adjusted cause-specific hazard ratio for disease-related treatment failure with LCCRT versus SCRT was 0.26 (95% CI, 0.08-0.87). Three-year cumulative probability of disease-related treatment failure was 10.0% and 25.6% for LCCRT and SCRT, respectively. No significant differences in T-downstaging, Ndownstaging, significant pathologic downstaging (ypT0-2N0), locoregional failure, distant metastasis, or overall survival were found. Late rectal toxicity occurred in 10 (15%) LCCRT and two (3%) SCRT patients, respectively. Conclusion: LCCRT with consolidative chemotherapy demonstrated improved disease-related treatment failure compared with SCRT, despite higher late rectal toxicity. Further research is needed to assess the long-term oncologic outcomes and toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype

Author

Hong, Theodore S., Wo, Jennifer Y., Borger, Darrell R., Yeap, Beow Y., McDonnell, Erin I., Willers, Henning, Blaszkowsky, Lawrence S., Kwak, Eunice L., Allen, Jill N., Clark, Jeffrey W., Tanguturi, Shyam, Goyal, Lipika, Murphy, Janet E., Wolfgang, John A., Drapek, Lorraine C., Arellano, Ronald S., Mamon, Harvey J., Mullen, John T., Tanabe, Kenneth K., Ferrone, Cristina R., and Zhu, Andrew X.

Published
2017
Full Text
View/download PDF

29. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).

Author

Basch, Ethan, Dueck, Amylou C., Mitchell, Sandra A., Mamon, Harvey, Weiser, Martin, Saltz, Leonard, Gollub, Marc, Rogak, Lauren, Ginos, Brenda, Mazza, Gina L., Colgrove, Brian, Chang, George, Minasian, Lori, Denicoff, Andrea, Thanarajasingam, Gita, Musher, Benjamin, George, Thomas, Venook, Alan, Farma, Jeffrey, and O'Reilly, Eileen

Published
2023
Full Text
View/download PDF

30. Comparison of MR‐soft tissue based versus biliary stent based alignment for image guidance in pancreatic SBRT.

Author

Han, Zhaohui, Sudhyadhom, Atchar, Hsu, Shu‐Hui, Hu, Yue‐Houng, Mak, Raymond H., Huynh, Mai Anh, van Dams, Ritchell R., Tanguturi, Shyam, Venkatachalam, Veena, Mancias, Joseph D., Mamon, Harvey J., Martin, Neil E., Lam, Miranda B., and Leeman, Jonathan E.

Subjects
IMAGE registration, CONE beam computed tomography, LARGE intestine, PANCREATIC duct, SMALL intestine, LINEAR accelerators, FRACTIONS, PANCREAS
Abstract

Purpose: The role of biliary stents in image‐guided localization for pancreatic cancer has been inconclusive. To date, stent accuracy has been largely evaluated against implanted fiducials on cone beam computed tomography. We aim to use magnetic resonance (MR) soft tissue as a direct reference to examine the geometric and dosimetric impacts of stent‐based localization on the newly available MR linear accelerator. Methods: Thirty pancreatic cancer patients (132 fractions) treated on our MR linear accelerator were identified to have a biliary stent. In our standard adaptive workflow, patients were set up to the target using soft tissue for image registration and structures were re‐contoured on daily MR images. The original plan was then projected on treatment anatomy and dose predicted, followed by plan re‐optimization and treatment delivery. These online predicted plans were soft tissue‐based and served as reference plans. Retrospective image registration to the stent was performed offline to simulate stent‐based localization and the magnitude of shifts was taken as the geometric accuracy of stent localization. New predicted plans were generated based on stent‐alignment for dosimetric comparison. Results: Shifts were within 3 mm for 90% of the cases (mean = 1.5 mm); however, larger shifts up to 7.2 mm were observed. Average PTV coverage dropped by 1.1% with a maximum drop of 26.8%. The mean increase in V35Gy was 0.15, 0.05, 0.02, and 0.02 cc for duodenum, stomach, small bowel and large bowel, respectively. Stent alignment was significantly worse for all metrics except for small bowel (p = 0.07). Conclusions: Overall discrepancy between stent‐ and soft tissue‐alignment was modest; however, large discrepancies were observed for select cases. While PTV coverage loss may be compensated for by using a larger margin, the increase in dose to gastrointestinal organs at risk may limit the role of biliary stents in image‐guided localization. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Hypofractionation: Contracting or Expanding Disparities in the Receipt of Radiation Therapy?

Author

Diaz Pardo, Alexandra, Mamon, Harvey, and Jimenez, Rachel

Subjects
TUMOR prevention, RACISM, SOCIAL determinants of health, SERIAL publications, RADIOTHERAPY, HEALTH equity, BREAST tumors, PROSTATE tumors
Abstract

The article presents the discussion on stereotactic body radiotherapy (SBRT) for patients with lung cancer and decreasing access to proton therapy by race and socioeconomic status. Topics include significant influence on access to radiation oncology centers where studies showing the radiation oncology facilities primarily centered in metropolitan and urban areas; and patients living at an increased distance from radiotherapy centers being less likely to undergo needed radiotherapy.

Published
2023
Full Text
View/download PDF

46. Adjuvant treatment of colorectal cancer

Author

Wolpin, Brian M., Meyerhardt, Jeffrey A., Mamon, Harvey J., and Mayer, Robert J.

Subjects
Colorectal cancer -- Care and treatment, Cancer -- Adjuvant treatment, Cancer -- Forecasts and trends, Market trend/market analysis, Health
Published
2007

48. Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.

Author

Kharofa, Jordan R., Yothers, Greg, Kachnic, Lisa A., Ajani, Jaffer, Meyer, Joshua E., Augspurger, Mark E., Okawara, Gordon S., Garg, Madhur K., Schefter, Tracey E., Swanson, Todd A., Doncals, Desiree E., Kim, Hyun, Zaki, Bassem I., Narayan, Samir, Lee, R. Jeffery, Mamon, Harvey J., Schwartz, Michael A., Moughan, Jennifer, and Crane, Christopher H.

Published
2022
Full Text
View/download PDF

50. Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.

Author

Cooper, Lisa, Dezube, Aaron R., De León, Luis E., Kucukak, Suden, Mazzola, Emanuele, Dumontier, Clark, Mamon, Harvey, Enzinger, Peter, Jaklitsch, Michael T., Frain, Laura N., and Wee, Jon O.

Subjects
OLDER people, ESOPHAGEAL cancer, CHEMORADIOTHERAPY, OVERALL survival, AGE groups, TERMINATION of treatment
Abstract

Chemoradiotherapy for Esophageal cancer followed by Surgery (CROSS regimen) is standard of care for locally-advanced esophageal cancer. We evaluated CROSS completion rates, toxicity, and postoperative outcomes between older and younger adults receiving trimodality therapy. Retrospective analysis of patients with locally-advanced esophageal cancer who underwent CROSS regimen from May 2016 to January 2020 at a single academic center. Outcomes of those aged ≥70-years-old and <70 years-old were analyzed. Of 201 patients, 136 were <70 and 65 were ≥70 years. Older adults were more likely to be male (91% vs. 79%; p = 0.045), have higher ECOG scores (median 1 vs. 0; p = 0.003), Charlson-comorbidity index (median 6 vs. 4; p < 0.001), and undergo open procedures (20% vs. 8% p = 0.008). Most completed CROSS regimen (78% vs. 84% respectively) with similar rates of treatment discontinuation and dose reduction (all p > 0.05). Time to surgery following neoadjuvant therapy was similar between age groups, except in those ≥80-years-old as compared to <70-years-old (p < 0.05). Overall toxicity rates were similar (68% vs. 71% respectively; p = 0.676). Only rates of delirium (19% vs. 5%) and urinary retention (9% vs. 0%) were higher in older adults (both p < 0.05). Length of stay, discharge disposition, mortality, and overall survival were similar. Age was not an independent risk factor for complication, neoadjuvant toxicity or completion, surgery timing, nor worse overall or recurrence-free survival (p > 0.05). Trimodality CROSS regimen for esophageal cancer in older adults is feasible, with similar completion rates and postoperative outcomes as compared to their younger counterparts. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results